Edition:
United Kingdom

Hitachi Chemical Co Ltd (4217.T)

4217.T on Tokyo Stock Exchange

1,623JPY
14 Dec 2018
Change (% chg)

¥-48 (-2.87%)
Prev Close
¥1,671
Open
¥1,631
Day's High
¥1,650
Day's Low
¥1,604
Volume
1,046,700
Avg. Vol
1,141,990
52-wk High
¥3,115
52-wk Low
¥1,513

Latest Key Developments (Source: Significant Developments)

Thai Storage Battery Enters License Agreement With Hitachi Chemical
Monday, 12 Nov 2018 

Nov 12 (Reuters) - Thai Storage Battery Pcl ::GROUP ENTERED INTO LICENSE AGREEMENT WITH HITACHI CHEMICAL FOR USE OF HITACHI BRAND WITH RIGHT OF SUBLICENSE.RATE OF FEES BETWEEN HITACHI CHEMICAL, & CO SHALL BE 1 PERCENT OF CONSOL SALES REVENUE FOR THE BUSINESS YEAR WITH SEMIANNUAL PAYMENTS.  Full Article

Hitachi Chemical Advanced Therapeutics Solutions Says Signed A Three-Year Clinical Manufacturing Agreement With GSK
Monday, 1 Oct 2018 

Oct 1 (Reuters) - GlaxoSmithKline PLC ::HITACHI CHEMICAL ADVANCED THERAPEUTICS SOLUTIONS SAYS SIGNED A THREE-YEAR CLINICAL MANUFACTURING AGREEMENT WITH GSK.HITACHI CHEMICAL ADVANCED THERAPEUTICS SAYS CO TO MANUFACTURE GSK'S SPEAR T-CELL RECEPTOR THERAPY TARGETING NY-ESO-1 FOR U.S., CANADIAN, EUROPEAN TRIALS.HITACHI CHEMICAL ADVANCED THERAPEUTICS SOLUTIONS SAYS SIGNED A THREE-YEAR CLINICAL MANUFACTURING AGREEMENT WITH GSK.  Full Article

affirms Hitachi Chemical's rating at "A+" and announces outlook stable -R&I
Monday, 26 Mar 2018 

March 26(Reuters) - Hitachi Chemical Co Ltd <4217.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Says rating outlook stable -R&I.  Full Article

Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex
Thursday, 4 Jan 2018 

Jan 4(Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd <<<4217.T>>>, on Jan. 4 .  Full Article

Hitachi Chemical to buy remaining 80.1% interest in PCT from Caladrius
Thursday, 16 Mar 2017 

Hitachi Chemical Co Ltd <4217.T> :Hitachi chemical signs agreement to purchase from caladrius biosciences remaining 80.1% interest in percent for $75 million.  Full Article